Diagnosys LLC
USPTO PatentsView assignee record - 7 granted patents across 6 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).
The verdict
According to USPTO PatentsView, Diagnosys ranks #35,008 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 6 technology areas.
- #35,008
- of 49,997 US assignees by volume
- Top 44%
- by Innovation Score (37.4/100)
- 24.9
- avg claims per patent
USPTO PatentsView assignee plate
Corpus R35008 · US Corporation #35,008 · 7 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH
- GRANTS-MICRO 7 grants
- MID-PACK #35,008/49,997
- PHOTO-FINISH Development
- CPC-NARROW A61B · 6 areas
- INNOV-THIN 37.4/100
- CLAIMS-DENSE 24.9 claims/avg
- TYPE-USCORP US Corporation
- SPAN-YRS 2020–2025 · 6y
- BOOK-RICH 9/10 fields
Nearest grant-volume peer: Development LLC (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Diagnosys’s 37.4 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Diagnosys
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Diagnosys · this assignee
Diagnosys · this assignee
37 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Diagnosys's Innovation Score is 37.4/100 (top 44% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Diagnosys?
Each dot is one of Diagnosys’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Diagnosys’s own 24.9 claims/patent is ABOVE the 18.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Diagnosys's grants concentrate
Diagnosys LLC is a focused PatentsView assignee: 6 CPC subclasses with 85.7% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2020 (2 grants) versus a trough of 1 in 2021. By volume, Diagnosys sits between Development LLC and Didimo, Inc..
Diagnosys's three-year grant acceleration
Diagnosys LLC shows 3 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Diagnosys's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Development
Development LLC
7 patents
- Dexcare
DexCare, Inc.
7 patents
- Diamon Tech
DiaMon Tech AG
7 patents
- Diageo Brands B V
Diageo Brands B.V.
7 patents
- Diakopto
Diakopto, Inc.
7 patents
- Dialware
Dialware Inc
7 patents
- Diamond Products
Diamond Products Limited
7 patents
- Didimo
Didimo, Inc.
7 patents
- Diagnosys ◀
Diagnosys LLC
7 patents
What this shows Diagnosys holds 7 patents at rank #35,046, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Diagnosys
By rank, the assignees closest to #35,046 in granted patent volume.
Leaders in A61B (Diagnosis)
Other assignees with the most granted patents in Diagnosys's primary technology class.
- Covidien LP 5,709 in class
- Koniniklijke Philips N.V. 3,414 in class
- Olympus Corporation 2,758 in class
- Boston Scientific Scimed, Inc. 2,362 in class
- Cilag GmbH International 2,063 in class
- Intuitive Surgical Operations, Inc. 1,921 in class
- DePuy Synthes Products, Inc. 1,796 in class
- Ethicon, Inc. 1,762 in class
Diagnosys's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
37 Top 44% higher than 56% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 2 | 28.6% |
| 2021 | 1 | 14.3% |
| 2022 | 2 | 28.6% |
| 2024 | 1 | 14.3% |
| 2025partial year | 1 | 14.3% |
Which technologies does Diagnosys LLC patent most?
Top 6 of 6 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Diagnosys LLC's patent record in context - here's where to go next.
- Diagnosys LLC's lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 85.7% of its portfolio - see every assignee active in that class. Explore A61B
- Ranked #35,008 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Diagnosys LLC against Development LLC, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 37.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.